Comprehensive Introduction to Conventional TACE
Transarterial Chemoembolization, commonly referred to as TACE, is a minimally invasive, image-guided procedure used primarily to treat primary liver cancer (Hepatocellular Carcinoma - HCC) and metastatic liver disease. Conventional TACE (cTACE) involves the direct delivery of a concentrated dose of chemotherapy drugs into the hepatic artery, which supplies the tumor, followed by the injection of embolic agents to block the blood supply.
By combining chemotherapy and ischemia (lack of blood flow), cTACE provides a dual-action attack on tumors that cannot be treated with surgery or ablation. This guide serves as an authoritative resource for patients and medical professionals seeking to understand the technical, clinical, and procedural nuances of cTACE.
The Mechanism: How Conventional TACE Works
The physics and physiological mechanism of cTACE rely on the unique dual blood supply of the liver. The liver receives approximately 75% of its blood from the portal vein and 25% from the hepatic artery. However, liver tumors—specifically HCC—derive nearly 100% of their blood supply from the hepatic artery.
The Two-Step Mechanism
- Chemotherapy Delivery: A chemotherapeutic agent (most commonly Doxorubicin or Mitomycin C) is mixed with an embolic carrier, typically Lipiodol (an iodized oil). This mixture is injected directly into the tumor's feeding artery.
- Embolization: Following the chemotherapy, embolic particles (such as gelatin sponge or polyvinyl alcohol) are introduced to occlude the artery. This traps the chemotherapy within the tumor and creates hypoxia, which accelerates tumor cell death.
| Component | Function |
|---|---|
| Lipiodol | Acts as a carrier for the drug; accumulates in tumor cells. |
| Chemotherapy | Induces cytotoxic effects to kill malignant cells. |
| Embolic Agents | Prevents the drug from washing out and starves the tumor of oxygen. |
Extensive Clinical Indications & Usage
TACE is generally reserved for patients who are not candidates for curative treatments like liver resection or transplantation. It is part of the BCLC (Barcelona Clinic Liver Cancer) staging system for intermediate-stage HCC.
Primary Indications
- Hepatocellular Carcinoma (HCC): The most common indication for patients with multinodular disease without vascular invasion.
- Liver Metastases: Specifically neuroendocrine tumors or colorectal cancer metastases that are unresectable.
- Bridge to Transplant: Used to prevent tumor progression while a patient is on the waiting list for a liver transplant.
- Downstaging: Used to shrink a large tumor to a size where it may eventually become eligible for surgical resection.
Contraindications
Patients must be carefully screened to avoid severe complications. Absolute contraindications include:
* Severe liver failure (Child-Pugh C).
* Portal vein thrombosis (where the main portal vein is completely occluded).
* Severe renal insufficiency.
* Systemic infection or sepsis.
The Procedure: Step-by-Step
The procedure is performed by an Interventional Radiologist in a sterile angiography suite.
1. Preparation
- Pre-procedure imaging: CT or MRI scans are reviewed to map the liver’s vascular anatomy.
- Laboratory assessment: Coagulation profiles (INR, PTT) and liver function tests (LFTs) are mandatory.
- Sedation: Patients are typically placed under moderate or conscious sedation.
2. Access and Navigation
The radiologist makes a small incision in the groin (femoral artery) or wrist (radial artery). A catheter is guided under fluoroscopic guidance through the aorta and into the hepatic artery.
3. Angiography
A contrast dye is injected to visualize the tumor’s vascular bed. The radiologist identifies the specific arterial branches feeding the tumor to avoid damaging healthy liver tissue.
4. Embolization and Infusion
The chemotherapy-Lipiodol emulsion is injected. Once the tumor bed is saturated, the embolic material is deployed to "seal" the artery.
5. Post-Procedure
The catheter is removed, and pressure is applied to the access site to prevent bleeding. The patient is monitored in the recovery unit for several hours.
Risks and Radiation Exposure
While cTACE is considered safe, it is an invasive procedure with inherent risks.
- Post-Embolization Syndrome (PES): Affects up to 80% of patients. Symptoms include low-grade fever, abdominal pain, nausea, and fatigue. This is a normal inflammatory response and typically resolves within a week.
- Liver Function Decline: Because the procedure affects liver blood flow, there is a risk of transient or permanent liver injury.
- Infection: Risk of liver abscess, though this is rare with prophylactic antibiotics.
- Radiation Exposure: The procedure uses fluoroscopy (X-rays). While the radiation dose is generally kept low, the duration of the procedure can lead to skin irritation in rare cases.
Interpretation of Results
Success is measured via follow-up imaging (MRI or CT) usually performed 4 to 8 weeks after the procedure.
- Normal (Successful) Result: The tumor shows "Lipiodol retention" on a CT scan—appearing bright white—indicating the drug has successfully saturated the lesion. There is a lack of "arterial phase enhancement," meaning the tumor no longer has active blood flow.
- Abnormal (Recurrent) Result: The presence of new arterial enhancement within or around the treated tumor suggests residual disease or recurrence, indicating the need for repeat TACE or a change in therapy.
Massive FAQ Section
1. Is cTACE a cure for liver cancer?
TACE is generally considered a palliative or life-extending treatment rather than a curative one. However, it can successfully manage disease for years.
2. How long does the procedure take?
Typically, the procedure lasts between 60 to 90 minutes, depending on the complexity of the vascular anatomy.
3. How many TACE sessions are required?
This varies by patient. Some tumors respond after one session, while others require a series of treatments spaced 4–6 weeks apart.
4. Will I lose my hair like in systemic chemotherapy?
No. Because the chemotherapy is delivered directly into the liver, systemic side effects are significantly minimized compared to intravenous chemotherapy.
5. Is the procedure painful?
Patients are sedated and receive local anesthesia. Some abdominal cramping may occur during the injection, but it is managed with intravenous pain medication.
6. What is the recovery time?
Most patients stay in the hospital for 24 hours for observation and return to normal daily activities within 7 to 10 days.
7. Can TACE be performed if I have cirrhosis?
Yes, but the extent of the cirrhosis (Child-Pugh score) must be evaluated to ensure the liver can tolerate the procedure.
8. What is the difference between cTACE and DEB-TACE?
Conventional TACE uses an oil-based carrier (Lipiodol), while DEB-TACE (Drug-Eluting Bead) uses specialized microscopic beads that release the drug slowly over time.
9. What should I eat before the procedure?
Patients are generally required to fast for 6 to 8 hours before the procedure to minimize the risk of nausea from sedation.
10. Can I drive home after the procedure?
No. Due to the sedation used during the procedure, you must arrange for someone else to drive you home.
Conclusion
Conventional TACE remains a cornerstone of interventional oncology. By leveraging the specific vascular anatomy of the liver, it delivers potent therapy directly to the tumor while sparing the rest of the body. While it involves risks and requires careful post-procedural management, it continues to provide significant survival benefits for thousands of patients annually. Always consult with your interventional radiologist and hepatologist to determine if cTACE is the right path for your specific clinical staging.